Worst Pain Intensity

Biomarker

Related News

Immunome Submits NDA for Varegacestat in Desmoid Tumors After Positive Phase 3 RINGSIDE Trial

Apr 29, 2026

Immunome submitted an NDA to the FDA for varegacestat in desmoid tumors after the Phase 3 RINGSIDE trial showed an 84% reduction in progression risk (HR=0.16) and a 56% objective response rate. The company plans to file in Q2 2026.

PSMAddition shows rPFS benefit for 177Lu-PSMA-617 triplet in PSMA-positive mHSPC

Apr 06, 2026

Phase 3 PSMAddition showed that adding 177Lu-PSMA-617 to ADT plus an ARPI improved radiographic progression-free survival in PSMA-positive mHSPC. Health-related quality of life and pain were largely maintained.